Next-Generation Stool DNA Test Accurately Detects Colorectal Cancer and Large Adenomas
Background & Aims
Technical advances have led to stool DNA (sDNA) tests that might accurately detect neoplasms on both sides of the colorectum. We assessed colorectal neoplasm detection by a next-generation sDNA test and effects of covariates on test performance.
Methods
We performed a blinded, multicenter, case-control study using archived stool samples collected in preservative buffer from 252 patients with colorectal cancer (CRC), 133 with adenomas ≥1 cm, and 293 individuals with normal colonoscopy results (controls); two-thirds were randomly assigned to a training set and one-third to a test set. The sDNA test detects 4 methylated genes, a mutant form of KRAS, and the α-actin gene (as a reference value) using quantitative, allele-specific, real-time target and signal amplification; it also quantifies hemoglobin. We used a logistical model to analyze data.
Results
The sDNA test identified 85% of patients with CRC and 54% of patients with adenomas ≥1 cm with 90% specificity. The test had a high rate of detection for all nonmetastatic stages of CRC (aggregate 87% detection rate for CRC stages I−III). Detection rates increased with adenoma size: 54% ≥1 cm, 63% >1 cm, 77% >2 cm, 86% >3 cm, and 92% >4 cm (P < .0001). Based on receiver operating characteristic analysis, the rate of CRC detection was slightly greater for the training than the test set (P = .04), whereas the rate of adenoma detection was comparable between sets. Sensitivities for detection of CRC and adenoma did not differ with lesion site.
Conclusions
Early-stage CRC and large adenomas can be detected throughout the colorectum and with high levels of accuracy by the sDNA test. Neoplasm size, but not anatomical site, affected detection rates. Further studies are needed to validate the findings in a larger population and optimize the sDNA test.
Keywords: QuARTS , Colorectal Cancer Screening , Stool Testing , Precancer Detection
Abbreviations used in this paper: CRC, colorectal cancer, ROC, receiver operating characteristic, sDNA, stool DNA
To access this article, please choose from the options below
This article has an accompanying continuing medical education activity on page e25. Learning Objective: Upon completion of this CME activity, successful learners will be able to appraise the early clinical performance of a next-generation stool DNA test for detection of colorectal cancer and large adenomas.
Conflicts of interest These authors disclose the following: Dr Ahlquist and Mr Taylor are inventors of licensed technology. Drs Ahlquist and Vogelstein are scientific advisors to Exact Sciences. Drs Zou, Domanico, Berger, and Lidgard are employees of Exact Sciences. Mayo Clinic has licensed intellectual property to and is a minor equity investor in Exact Sciences. The remaining authors disclose no conflicts.
Funding Exact Sciences Corporation, National Institutes of Health grant CA 62924, and grants from Charles Oswald Foundation and Virginia and D.K. Ludwig Fund for Cancer Research.
PII: S0016-5085(11)01505-8
doi:10.1053/j.gastro.2011.10.031
© 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

